Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane

[1]  D. Collins,et al.  Inhibition of angiogenesis by antiestrogens. , 1993, Cancer research.

[2]  S. Steinberg,et al.  Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Chawnshang Chang,et al.  Basic fibroblast growth factor in human prostate cancer cells. , 1992, Cancer research.

[4]  R. Sasada,et al.  Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. , 1991, Cancer research.

[5]  D. Rifkin,et al.  Release of basic fibroblast growth factor, an angiogenic factor devoid of secretory signal sequence: A trivial phenomenon or a novel secretion mechanism? , 1991, Journal of cellular biochemistry.

[6]  F. Bazer,et al.  Antiproliferative activity of a pregnancy recognition hormone, ovine trophoblast protein-1. , 1991, Cancer research.

[7]  E. Woltering,et al.  Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. , 1991, The Journal of surgical research.

[8]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[9]  R. Danesi,et al.  Suramin, a novel antitumor compound , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[10]  D. Ingber,et al.  Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth , 1990, Nature.

[11]  T. Maione,et al.  Development of angiogenesis inhibitors for clinical applications. , 1990, Trends in pharmacological sciences.

[12]  E. A. Chiocca,et al.  Inhibition of growth and angiogenesis of human neurofibrosarcoma by heparin and hydrocortisone. , 1990, Journal of neurosurgery.

[13]  M. Klagsbrun,et al.  Autocrine transformation by chimeric signal peptide-basic fibroblast growth factor: reversal by suramin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Toulmé,et al.  Specific regulation of gene expression by antisense, sense and antigene nucleic acids. , 1990, Biochimica et biophysica acta.

[15]  S. Newman,et al.  An assay for heparin by decrease in color yield (DECOY) of a protein-dye-binding reaction. , 1990, Analytical biochemistry.

[16]  V. Baldin,et al.  Translocation of bFGF to the nucleus is G1 phase cell cycle specific in bovine aortic endothelial cells. , 1990, The EMBO journal.

[17]  B. Spiegelman,et al.  1-Butyryl-Glycerol: A novel angiogenesis factor secreted by differentiating adipocytes , 1990, Cell.

[18]  J. Supko,et al.  A Rapid Isocratic HPLC Assay of Suramin (NSC 34936) in Human Plasma , 1990 .

[19]  M. Herlyn,et al.  Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. , 1989, The EMBO journal.

[20]  M. Maragoudakis,et al.  Antiangiogenic action of heparin plus cortisone is associated with decreased collagenous protein synthesis in the chick chorioallantoic membrane system. , 1989, The Journal of pharmacology and experimental therapeutics.

[21]  N. Quarto,et al.  Transformation of NIH 3T3 cells with basic fibroblast growth factor or the hst/K-fgf oncogene causes downregulation of the fibroblast growth factor receptor: reversal of morphological transformation and restoration of receptor number by suramin , 1989, The Journal of cell biology.

[22]  C. Stein,et al.  Suramin: an anticancer drug with a unique mechanism of action. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Chandler,et al.  Quantitation of corneal neovascularization using computerized image analysis. , 1988, Laboratory investigation; a journal of technical methods and pathology.

[24]  Ana D. Lopez,et al.  An in vivo model for study of the angiogenic effects of basic fibroblast growth factor. , 1987, Biochemical and biophysical research communications.

[25]  R. Coffey,et al.  Suramin inhibition of growth factor receptor binding and mitogenicity in AKR‐2B cells , 1987, Journal of cellular physiology.

[26]  J. Fiddes,et al.  Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor. , 1986, Science.

[27]  G. Chrousos,et al.  The Effect of Serum Prolactin on Plasma Adrenal Androgens and the Production and Metabolic Clearance Rate of Dehydroepiandrosterone Sulfate in Normal and Hyperprolactinemic Subjects , 1986, The Journal of clinical endocrinology and metabolism.

[28]  R. Langer,et al.  Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. , 1983, Science.

[29]  B. Dunn,et al.  Effects of varying chamber construction and embryo pre‐incubation age on survival and growth of chick embryos in shell‐less culture , 1981, The Anatomical record.

[30]  D. Gospodarowicz,et al.  Clonal growth of bovine vascular endothelial cells: fibroblast growth factor as a survival agent. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[31]  L. Vrba,et al.  Inhibition of angiogenesis with combination treatments of angiostatic steroids and suramin. , 1991, International journal of radiation biology.

[32]  W. Risau,et al.  Angiogenic growth factors. , 1990, Progress in growth factor research.

[33]  D. Kamp,et al.  Transforming growth factor-beta (TGF beta) is chemotactic for human monocytes and induces their expression of angiogenic activity. , 1988, Biochemical and biophysical research communications.

[34]  P. Burger,et al.  An evaluation of methods to quantitate the chick chorioallantoic membrane assay in angiogenesis. , 1985, Laboratory investigation; a journal of technical methods and pathology.

[35]  F. Hawking.  Suramin: with special reference to onchocerciasis. , 1978, Advances in pharmacology and chemotherapy.